OPNT, Opiant Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Opiant Pharmaceuticals Stock Quote: OPNT Stock News, Quotes, Analysis | Investors.com

Opiant Pharmaceuticals News: This is the News-site for the company Opiant Pharmaceuticals on Markets Insider

Latest Share Price and Events. Stable Share Price: OPNT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week. 2021-04-05 2020-06-09 Get Opiant Pharmaceuticals Inc (OPNT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Stock analysis for Opiant Pharmaceuticals Inc (OPNT:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Enjoy the benefits at Opiant. Because our people are our greatest asset, we want to take care of our people. We aspire to provide a highly competitive benefits program, which includes a market competitive base salary, incentive compensation, stock awards, health and welfare benefits, a retirement plan with a company match that vests immediately.

Opiant pharmaceuticals news

Law360 (June 5, 2020, 10:43 PM EDT) -- A New Jersey federal judge found that claims from four patents related to Narcan, the nasal spray treatment for opioid overdoses, are invalid Friday, handing a win to Teva Pharmaceuticals USA Inc. in a suit from the treatment's licensor and licensee Opiant Pharmaceuticals Inc. and Adapt Pharma Operations Ltd. Read current news for OPNT (XNAS). Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, … Company profile page for Opiant Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020 SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ( The yearly results for Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) were released last week, making it a good time to revisit its performance.The results don't look great, especially considering that statutory losses grew 97% toUS$0.44 per share. Revenues of US$30m did beat expectations by 2.5%, but it looks like a bit of a cold comfort. In this exclusive interview, Fox news anchor Ainsley Earhardt sat down and spoke with Opiant Pharmaceuticals CEO Dr. Roger Crystal to discuss the opioid epid 2021-04-01 2021-03-31 Opiant Pharmaceuticals Inc in News. Benzinga (OPNT) The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks . Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company.

Quarterly Results Earnings per share decreased 180.00% over the past year to ($0.16), which missed SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of March 22, 2021 Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose SANTA MONICA, Calif.

Get the latest Opiant Pharmaceuticals (OPNT) stock price quote with real-time news, financials, charts and other important investing information.

Proxy Statement - Merger or Acquistion (preliminary) (prem14a) Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose. We are headquartered in Santa Monica, with additional offices in London, UK. We were founded in 2009. In 2013, Opiant developed the first FDA-approved, user-friendly nasal naloxone spray. Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Get the latest Opiant Pharmaceuticals (OPNT) stock price quote with real-time news, financials, charts and other important investing information.

Consort Medical Plc has agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc .

, March 31, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions… 2020-12-10 · Opiant Pharmaceuticals News: This is the News-site for the company Opiant Pharmaceuticals on Markets Insider 2020-12-10 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit 2021-03-31 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information, visit Find the latest Opiant Pharmaceuticals, Inc. (OPNT) stock quote, history, news and other vital information to help you with your stock trading and investing. 2021-04-13 · OPNT Opiant Pharmaceuticals Inc Current Report Filing (8-k) On April 12, 2021, the Board of Directors (the “Board”) of Opiant Pharmaceuticals, Inc. (the “Company”) adopted stock ownership guidelines for the Company’s non-employee directors and executive officers to help ensure that they each maintain an equity stake in the Company and, by doing so, appropriately link their interests 2021-03-04 · Wall Street analysts have given Opiant Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains.

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts 2 months ago | Simply Wall St Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years. OPIANT PHARMACEUTICALS, INC. : News, information and stories for OPIANT PHARMACEUTICALS, INC. | Nasdaq: OPNT | Nasdaq 2021-04-05 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4, 2021 at 2021-04-01 · Opiant Pharmaceuticals News: This is the News-site for the company Opiant Pharmaceuticals on Markets Insider Opiant Pharmaceuticals, Inc. (“we”, “our” or the “Company”) is a specialty pharmaceutical company developing medicines for addictions and drug overdose. We were incorporated in the State of Nevada in June 2005 as Madrona Ventures, Inc. and, in September 2009, we changed our name to Lightlake Therapeutics Inc. About us Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
I died in your arms tonight

Today's Range. $10.00. Now: $10.50 Opiant Pharmaceuticals News: This is the News-site for the company Opiant Pharmaceuticals on Markets Insider Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update. SANTA MONICA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals OPIANT PHARMACEUTICALS, INC. : News, information and stories for OPIANT PHARMACEUTICALS, INC. | Nasdaq: OPNT | Nasdaq View the latest Opiant Pharmaceuticals Inc. (OPNT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced its earnings results on Thursday, March, 4th. The technology company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.28.

17 maj 2018 — Oasmia Pharmaceutical AB kommer att presentera uppföljande resultat från den genomförda fas III-studien med Apealea® för behandling av Opiant, som är ett litet bolag med ett marknadsvärde på cirka 400 miljoner kronor, steg med 28 procent under börshandeln, rapporterar Bloomberg News. 20 mars 2018 — Detta rapporterar Reuters och Bloomberg News. Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet.
Nedläggning skolor gotland

epic analyst resume
guidning göteborgs hamn
epic analyst resume
technician
varma länder i oktober europa
finansforbundet løn
ikea köksplanering logga in

2021-04-05 · Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit

2021-03-15 · View the latest Opiant Pharmaceuticals Inc. (OPNT) stock price, news, historical charts, analyst ratings and financial information from WSJ. 2021-04-05 · About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN ® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com. Forward-Looking Statements This press release contains forward-looking statements. Enjoy the benefits at Opiant. Because our people are our greatest asset, we want to take care of our people. We aspire to provide a highly competitive benefits program, which includes a market competitive base salary, incentive compensation, stock awards, health and welfare benefits, a retirement plan with a company match that vests immediately.

Find the latest Opiant Pharmaceuticals, Inc. (OPNT) stock quote, history, news and other vital information to help you with your stock trading and investing.

2021-03-31 2021-03-04 2021-04-13 2021-04-08 2 days ago About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com. Forward-Looking Statements This press release contains forward-looking statements. Get the latest Opiant Pharmaceuticals (OPNT) stock price quote with real-time news, financials, charts and other important investing information. Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2020 Results - Earnings Call Transcript seekingalpha.com - August 9 at 8:10 AM: Opiant Pharmaceuticals EPS beats by $0.19, beats on revenue seekingalpha.com - August 6 at 9:08 PM: Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update 2021-04-05 A high-level overview of Opiant Pharmaceuticals, Inc. (OPNT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 2021-03-22 NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call … 2021-04-05 2021-04-13 About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose.

Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company. It is engaged in developing opioid antagonist treatments for substance use, addictive and eating disorders. Opiant Pharmaceuticals Inc., formerly known as Lightlake Therapeutics, Inc., is based in New York. 2019-01-01 Opiant Pharmaceuticals (OPNT) has been awarded the third and final tranche of$1.8M from the total grant of about $7.4M from the National Institute on Drug Abuse, part of the Roger Crystal has been the CEO of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) since 2009, and this article will examine the executive's compensation with respect to the overall performance of the company.This analysis will also assess whether Opiant Pharmaceuticals pays its CEO appropriately, considering recent earnings growth and total shareholder returns. About Opiant Pharmaceuticals Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions.